期刊文献+

静电纺丝技术制备载药聚乙烯醇-海藻酸钠纳米纤维 被引量:10

Preparation of Drug-Loaded Polyvinyl Alcohol-Sodium Alginate Nanofiber by Electrospinning
原文传递
导出
摘要 目的以盐酸莫西沙星作为模型药物,采用静电纺丝技术制备载药聚乙烯醇-海藻酸钠纳米纤维,并考察其释药性能。方法 采用星点设计-效应面优化法设计纳米纤维处方,考察聚乙烯醇、海藻酸钠的浓度、聚乙烯醇与海藻酸钠的比例对药物释放率的影响。以CaCl2乙醇溶液作为交联剂增加纳米纤维的抗水性能。通过光学显微镜和扫描电镜观察纳米纤维的形貌。检测载药率,并测定药物释放,对释放曲线进行拟合。结果 纳米纤维载药率均在65%以上。药物的释放符合Fick扩散定律,聚乙烯醇和海藻酸钠的浓度、两者比例与药物释放率之间符合二项式方程。结论制得的盐酸莫西沙星-聚乙烯醇-海藻酸钠纳米纤维显示出良好的释药特性,作为载药系统具有较好的应用前景。 OBJECTIVE To fabricate moxifloxacin hydrochloride-loaded polyvinyl alcohol (PVA)-sodium alginate (SA) nanofiher using the electrospinning technique and investigate the drug release in vitro. METHODS Central composite design-response surface methodology was used to investigate the influences of various factors, i. e. , PVA content, SA content, the ratio of PVA-SA, on the accumulated release rate of moxifloxacin hydrochloride from the nanofibers. The scaffolds were cross-linked by CaCl2 ethanol solution. Fiber morphology was characterized using optical microscope and scanning electron microscopy ( SEM ). Drug entrapment efficiency was determined, and drug release profiles were tested. RESULTS Moxifloxacin hydroehloride entrapment efficiencies were well above 65%. Drug was released from the nanofibers as a linear function of the square root of time, suggesting accordance with Fickian kinetics. The relationship between the independent variables and the dependent variables was in accordance with quadralic model. CONCLUSION The PVA-SA nanofiber presents good release characteristics, and has a good prospect as drug carrier.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第12期980-985,共6页 Chinese Pharmaceutical Journal
关键词 电纺纳米纤维 聚乙烯醇 海藻酸钠 释放度 electrospun nanofiber polyvinyl alcohol sodium alginate accumulated release rate
  • 相关文献

参考文献1

二级参考文献11

  • 1Aktas Z,GonulluN,SalciogluM,et a1.Moxifloxacin activity against clinical isolates compared with the activity Of ciprofloxacin.Int-J-Antimicrob-Agents,2002,20:196.
  • 2Krasemann C,MeyerJ,Tillotson G Evaluation Of the clinical microbiology profile of moxifioxacin.Clin Infect Dis,2001,32 Suppl l:S51-63.
  • 3Davidson RJ,Fuller J,Low DE.Pharmacodynamic properties of moxifloxacin,levofloxacin, and clarithromycin in S.pneumoniae and H.infiuenzae [abstract] 36th ICAAC;Sep 24;SanDiego:227.
  • 4JacobsE,DalhoffA,BrunnerU.Efficacy Of BAYl2-8039 in Mycoplasma pneumoniae infected guinea pigs .36th Interscience Conference On Antimicrobial Agents and Chemotherapy;1997 Sep 15-18:New Orleans,Louisiana:102.
  • 5Visalli MA,Jacobs MR,Appelbaum PC.Antipneumococcal activity Of BAYl3-8039,a new quinolone, compared with activities Of three other quinolones and four oral beta-lactams.Antimicrob Agents Chemother,1997,41:1786.
  • 6National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing:eleventh informational supplement .NCCLS documents.2002,78.
  • 7Coudron PE, Moland ES, Thomson KS. Occurrence and Detection Of AmpC Beta-Lactamase amone Escherichia coli,Klebsiella pneumoniae , and Proteus mirabilis isolates at a Veterans Medical Center.J. Clin Microb.2000,38(5),1791.
  • 8Sahm DF, Washington II JA.Antibacterial susceptibility tests:dilution methods.Manual of clinical microbiology, 6th ed.1995:1117.
  • 9National Committee for Clinical Laboratory Standards. Performance Standard for antimicrobial susceptibility testing: eleventh informational supplement .NCCLS documents.2001,93.
  • 10Jacobs MR,Appelbaum PC,Felmingham D.The Alexander project group. Penicillin resistance in S.pneumoniae.Clin Microbiol lnf.2000,6 Supple l:28.

共引文献33

同被引文献98

引证文献10

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部